FindTrial
Sign In

A Study of mTOR Inhibitor as Adjunctive Therapy in children With Tuberous Sclerosis Complex

A Study of mTOR Inhibitor as Adjunctive Therapy in children With Tuberous Sclerosis Complex

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOB-15006535
Enrollment
Unknown
Registered
2015-05-29
Start date
2015-05-26
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberous sclerosis complex

Interventions

Case series:rapamycin

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: The patients were diagnosed with tuberous sclerosis complex with the age between 1m-18 years. Gender is not confined.

Exclusion criteria

Exclusion criteria: Abnormal findings in routine blood test and liver and renal fnction examinations.Congenital immunodeficiency.

Design outcomes

Primary

MeasureTime frame
dwindle in size;systom improvement;—

Countries

China

Contacts

Public ContactZou Li-ping
zouliping21@hotmail.com+86 10 55499016

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 6, 2026